Kent Michael S, Mandrekar Sumithra J, Landreneau Rodney, Nichols Francis, DiPetrillo Thomas A, Meyers Bryan, Heron Dwight E, Jones David R, Tan Angelina D, Starnes Sandra, Putnam Joe B, Fernando Hiran C
Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Department of Health Sciences Research, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota.
Ann Thorac Surg. 2016 Jul;102(1):230-8. doi: 10.1016/j.athoracsur.2016.01.069. Epub 2016 Apr 19.
Sublobar resection (SR) in high-risk operable patients may result in a long-term decrease in pulmonary function. We previously reported 3-month pulmonary function outcomes from a randomized phase III study of SR alone compared with SR with brachytherapy in patients with non-small cell lung cancer. We now report long-term pulmonary function after SR.
Pulmonary function was measured at baseline and at 3, 12, and 24 months. A decline of 10% or more from baseline in the percentage predicted forced expiratory volume of 1 percentage or in the diffusion capacity of the lung for carbon monoxide was considered clinically meaningful. The effect of study arm, tumor location, size, approach (video-assisted thoracoscopic surgery vs thoracotomy), and SR type (wedge vs segmentectomy) on pulmonary function was assessed using a Wilcoxon rank sum test. A generalized estimating equation model was used to assess the effect of each factor on longitudinal data, including all four time points.
Complete pulmonary function data at all time points was available in 69 patients. No significant differences were observed in pulmonary function between SR and SR with brachytherapy, thus the study arms were combined for all analyses. A decline of 10% or more (p = 0.02) in the percentage predicted forced expiratory volume in 1 second was demonstrated for lower-lobe resections at 3 months but was not at 12 or 24 months. A decline of 10% or more (p = 0.05) in the percentage predicted diffusion capacity of the lung for carbon monoxide was seen for thoracotomy at 3 months but was not at 12 or 24 months.
Clinically meaningful declines in pulmonary function occurred after lower lobe resection and after thoracotomy at 3 months but subsequently recovered. This study suggests that SR does not result in sustained decreased pulmonary function in high-risk operable patients.
对高风险可手术患者进行肺叶下切除(SR)可能会导致肺功能长期下降。我们之前报告了一项随机III期研究的3个月肺功能结果,该研究比较了非小细胞肺癌患者单纯SR与SR联合近距离放疗的效果。我们现在报告SR后的长期肺功能情况。
在基线、3个月、12个月和24个月时测量肺功能。预计第1秒用力呼气量百分比或肺一氧化碳弥散量较基线下降10%或更多被认为具有临床意义。使用Wilcoxon秩和检验评估研究组、肿瘤位置、大小、手术方式(电视辅助胸腔镜手术与开胸手术)和SR类型(楔形切除术与肺段切除术)对肺功能的影响。使用广义估计方程模型评估每个因素对纵向数据(包括所有四个时间点)的影响。
69例患者在所有时间点均有完整的肺功能数据。单纯SR与SR联合近距离放疗之间的肺功能未观察到显著差异,因此在所有分析中将研究组合并。下叶切除术在3个月时第1秒用力呼气量预计百分比下降10%或更多(p = 0.02),但在12个月或24个月时未出现。开胸手术在3个月时肺一氧化碳弥散量预计百分比下降10%或更多(p = 0.05),但在12个月或24个月时未出现。
下叶切除术后和开胸手术后3个月出现了具有临床意义的肺功能下降,但随后恢复。本研究表明,SR不会导致高风险可手术患者的肺功能持续下降。